Verrica Pharmaceuticals Inc. reported second quarter 2026 financial results, posting total revenue of $5.9 million and a net loss of $13.2 million, or $0.62 per share. U.S. YCANTH product revenue increased 18.7% to $5.1 million, while dispensed applicator units grew 46.1% year-over-year to 19,626. The company recognized a $1.7 million expense for a legal settlement related to class action proceedings. Verrica also announced a new credit facility with an entity controlled by Chairman Paul B. Manning for up to $27.5 million, which management believes could extend the cash runway into 2028. Topline data from the global Phase 3 program for common warts is expected in mid-2027. Verrica Pharmaceuticals Inc. operates in the biotechnology industry, developing and commercializing medications for dermatological diseases.

At the 2026 Annual Meeting of Stockholders, Verrica Pharmaceuticals Inc. stockholders approved the Amended and Restated 2018 Equity Incentive Plan, which became effective immediately. The meeting results included the election of Paul B. Manning and Lawrence Eichenfield to the Board of Directors, the advisory approval of executive officer compensation, and the ratification of KPMG LLP as the independent auditor. Out of 17,178,786 shares outstanding, 81.89% of shares were present or represented by proxy. Verrica Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes commercial-stage products for skin diseases.